La inmunoterapia como cambio de paradigma - page 6

Long term-survival in 2L NSCLC
.
Gettinger SN. J Clin Oncol. 2015;33(18):2004-2012. 2. Borghaei H et al. Poster presentation at ASCO 2016. 9025. 3. Barlesi F et al. Oral
.
CA209-003: Nivo Monotherapy in NSCLC1
Time Since First Dose (months)
100
80
60
0
40
20
0 6 12 18 30 24 36 42 48 54 66 60
3-year OS=18%
2-year OS=24%
OS (%)
1-year OS=42%
Checkmate 017: Squamous NSCLC2
OS (%)
100
80
60
40
0
20
33 27 24 21 18 15 12 9 6 3 0 30
Docetaxel
2-yr OS =23%
2-yr OS=8%
Nivolumab
Time (months)
Checkmate 057: Non-squamous NSCLC2
Time (months)
27 18 15 9 6 21 12 3 0 24 30
100
80
60
40
0
20
OS(%)
Docetaxel
2-yr OS=29%
2-yr OS=16%
Nivolumab
OS (%)
18-mo OS=40%
100
80
60
40
20
0
0 3 6 9 12 15 18 21 24 27
Atezolizumab
Docetaxel                         

     
        
                           

         
  
18-mo OS=27%
Time (months)
OAK: NSCLC3
18-mo OS=37%
18-mo OS=43%
18-mo OS=24%
KN-010: ≥1% PD-L1 NSCLC4
Pembro 2 mg/kg
Docetaxel
Pembro 10 mg/kg
0 5
OS (%)
0
20
40
60
80
100
10 15 20 25 30